Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results

Interest in kidney transplant assay represents approximately 25% of US transplant volume
Company lays out land and expand strategy in transplant

IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders.

Read more at globenewswire.com